Supriya Lifescience Limited · NSE:SUPRIYA
Supriya Lifescience — Q2 & H1 FY27 Earnings Presentation
33 slides from Supriya Lifescience's earnings presentation, Nov 6, 2026
Slide 1: Supriya Lifescience Investor Presentation filing letter
SUPRIYA LIFESCIENCE LTD. _, e Creating true va lues that bind g loba l lzen ltlt November 6, 2026 To, BSE Limited National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers, Exchange Plaza, Plot no. C/1, G Block, Dalal Street, Bandra-Kurla Complex Mumbai- 400 001 Bandra (E), Mumbai - 400 051
Slide 2: Q2 & H1 FY27 Investor Presentation
SUPRIYA LIFESCIENCE LTD. Q2 & H1 FY27 Investor Presentation
Slide 3: Safe Harbour
Safe Harbour G SUPRIYA LIFESCIENCE LTD. This presentation and the accompanying slides (the “Presentation”), which have been prepared by Supriya Lifescience Limited (the “Company”), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to pur
Slide 4: Q2 & H1 FY27 Highlights
1FY27 Highlights Ss SUPRIYA LIFESCIENCE LTD.
Slide 5: Q2 FY27 Highlights
Q2 FY27 Highlights G SUPRIYA LIFESCIENCE LTD. Revenue EBITDA PBT PAT Quarterly INR 2,063.0 Mn INR 454.0 Mn INR 377.8 Mn INR 292.5 Mn 3.2% YoY 37.5% YoY 44.7% YoY 42.0% YoY Business Mix Revenue Contribution – By Region Regional Performance 43% 39% 37% 35% 34% 36% ■ Q2 FY26 21% 20% ■ Q1 FY27 12% ■ Q2
Slide 6: H1 FY27 Highlights
H1 FY27 Highlights G SUPRIYA LIFESCIENCE LTD. Revenue EBITDA PBT PAT Quarterly INR 3,960.4 Mn INR 928.6 Mn INR 785.7 Mn INR 532.9 Mn 14.8% YoY 25.3% YoY 32.1% YoY 37.5% YoY Business Mix Revenue Contribution – By Region Regional Performance 38% 39% 40% 33% ■ H1 FY26 19% 16% ■ H1 FY27 4% 4% 5% 2% Asia
Slide 7: Q2 & H1 FY27 - Y-o-Y Highlights
Q2 & H1 FY27 - Y-o-Y Highlights 6 SUPRIYA ~ LIFESCIENCE LTD. (in INR Mn) Revenue EBITDA PBT PAT 3.2% YoY 14.8% YoY 37.5% YoY 25.3% YoY 44.7% YoY 32.1% YoY 42.0% YoY 37.5% YoY 1243.6 852.2 1157.3 3960.4 928.6 3449.1 785.7 504.3 532.9 726.6 683.2 1998.3 2063.0 454.0 292.5 377.8 Q2FY26 Q2FY27 H1FY26 H1
Slide 8: Business Mix Revenue Contribution – By Therapy
Business Mix Revenue Contribution – By Therapy G SUPRIYA LIFESCIENCE LTD. Performance of the Top Therapeutic Areas 54% 48% 16% 12% 12% 9% 8% 6% 7% -- - - --- 4% 4% 2% 2% 2% Anesthetic Analgesic Anti-Histamine Vitamins Anti-Asthmatic Anti-Allergic Anti-hypertensive ■ H1FY26 ■ H1FY27 7
Slide 9: Profit & Loss Statement
Profit & Loss Statement G SUPRIYA LIFESCIENCE LTD. Particulars (INR Mn) Q2 FY27 Q2 FY26 Y-o-Y Q1 FY27 Q-o-Q H1 FY27 H1 FY26 Y-o-Y Revenue from Operations 2,063.0 1,998.3 3.2% 1,897.5 8.7% 3,960.4 3,449.1 14.8% Cost of Goods Sold 710.6 557.3 27.5% 563.9 26.0% 1,274.5 875.0 45.6% Employee Benefits Exp
Slide 10: Balance Sheet
Balance Sheet G SUPRIYA LIFESCIENCE LTD. INR Mn Assets Mar 26 Sep 26 Equity and Liabilities Mar 26 Sep 26 Non-current assets Equity (i) Property, plant and equipment 6,833 7,286 (i) Equity share capital 161 161 (ii) Right to Use Asset 45 48 (ii) Other equity 11,816 12,265 (iii)Capital Work in progre
Slide 11: Company Overview
J F SUPRIYA ny Overview Ss LIFESCIENCE LTD.
Slide 12: Business Overview
Business Overview G SUPRIYA LIFESCIENCE LTD. Global leader in Anti-histamines, Anti-Allergic, Vitamins, Anti-Asthamatics & Anesthetics 40+ APIs 120+ Countries 35,000 Sq.mts 932 KLPD Niche product basket Diversified operations with presence Manufacturing facility spread across Reactor capacity WHO-GM
Slide 13: Journey So Far
Journey So Far 6 SUPRIYA ~ LIFESCIENCE LTD. ~ 2022 ~ 2023 ~ 2024 2025 ~ 2026 • • • • • CEP (Certificate of The Company commenced ANVISA Approval Launch of three Commercialized CMO suitability ) renewed for operations at its Granted molecules including facility at Ambernath Pheniramine Maleate, new R
Slide 14: Backward Integrated Business Model
Backward Integrated Business Model G SUPRIYA LIFESCIENCE LTD. Supply Security + Low Price Risk + In-House Processes - Cost-competitive Structure Steady supply of essential raw Protection against market Less Dependence On External Increasing margins materials fluctuations Parties 20 products are back
Slide 15: Diversified Geographic Presence
Diversified Geographic Presence 6 SUPRIYA ~ LIFESCIENCE LTD. .. , -:t,·i A' •.,... _ .' . FY27 Product Updates Liquid Anesthetic Two new anesthetic liquid inhalation products launched from Ambernath in Q2FY27; scale-up expected in the coming quarters. ADHD Planning ~2 launches in ADHD FY26 Product U
Slide 16: Diversified Revenues with Extensive Global Presence
Diversified Revenues with Extensive Global Presence G SUPRIYA LIFESCIENCE LTD. Significant export presence, with low dependence on a … with balanced customer concentration specific geography Export sales, as a % of revenue from operations Share of top 10 customers, as a % of revenue from operations
Slide 17: Advanced Manufacturing
Advanced Manufacturing 6 SUPRIYA ~ LIFESCIENCE LTD. o Well defined areas for R&D, Quality Control (chemical, microbiology), Quality Assurance, dedicated areas for engineering maintenance, i 5 warehouse, raw materials, packaging materials and I I Manufacturing Blocks Clean Rooms finished goods stores
Slide 18: Ambernath Facility
Ambernath Facility G SUPRIYA LIFESCIENCE LTD. Facility Location R&D Manufacturing • The site spans 5,000 sqm, with 70% of the area • Dosage forms R&D being set up for tablets, capsules, • FDF facilities commissioned. constructed, located at Plot No. N-60, liquids, sterile forms. • Tablets, capsules,
Slide 19: R&D Capabilities
R&D Capabilities G SUPRIYA LIFESCIENCE LTD. Supported by R&D driven mindset • A team of 68+ scientists primarily focused on API and formulations process development across the value chain DSIR approved facility • Already started two R&D centres – 4* o Ambernath R&D – Formulations and Generic APIs Pr
Slide 20: CMO Capabilities
CMO Capabilities G SUPRIYA LIFESCIENCE LTD. • State-of-the-art, GMP compliant manufacturing facility along with pilot facility for scale up available for trials before validation • Complete support in validation, stability, & compilation of dossiers • Dedicated technology transfer team is periodical
Slide 21: Complex Chemistries & Reaction (1/2)
Complex Chemistries & Reaction (1/2) G SUPRIYA LIFESCIENCE LTD. Focus on uniform manufacturing standards to achieve standardised product quality across markets … across varied class of reactions Ability to handle complex chemistries.. High vacuum distillations Simple to highly complex chiral Cyclisa
Slide 22: Complex Chemistries & Reaction (2/2)
Complex Chemistries & Reaction (2/2) G SUPRIYA LIFESCIENCE LTD. Focus on uniform manufacturing standards to achieve standardised product quality across markets … across varied class of reactions Ability to handle complex chemistries.. Chiral molecules synthesis using Chiral auxiliary Contrast media
Slide 23: Regulatory Achievements
Regulatory Achievements G SUPRIYA LIFESCIENCE LTD. Strong focus on compliance guided by ethical approach • Our motto is to consistently meet the stringent requirements of regulatory bodies • Supported by a skilled team of regulatory affairs experts dedicated to the timely submission of dossiers and
Slide 24: Awards & Accreditation
Awards & Accreditation G SUPRIYA LIFESCIENCE LTD. 2016 2017 2019 • Export House for the Year for 2015-16 awarded by • Export House for the Year for 2016-17 awarded by • Outstanding Export Performance Award for the year Directorate of Directorate of Industries, Government of Maharashtra 2018-19 for p
Slide 25: Key Management Team
Key Management Team G SUPRIYA LIFESCIENCE LTD. Satish Wagh Executive Chairman & WTD • An honorary Ph.D. in entrepreneurship from Faculty of Management Studies, National American University. • B.Sc. from R.D National College and W.A. Science College, University of Bombay. • Director on the board of S
Slide 26: EHS
EHS G SUPRIYA LIFESCIENCE LTD. Environment Health Safety • Strict monitoring for high-efficiency pollution control; • Clean, safe and healthy working environment for our • Commitment to safe, accident-free operations across focus on solvent recovery and reduced emissions all employees facilities • S
Slide 27: CSR & Social Work
CSR & Social Work G SUPRIYA LIFESCIENCE LTD. We believe true corporate citizenship is rooted in giving back to society, recognizing our responsibility extends beyond business paradigm • Regular activities hosted in the head office and factory for donations of utilities, clothes, school supplies from
Slide 28: Historical Financial Performance
Historical Financial Performance
Slide 29: Consistent & Strong Financial Performance
Consistent & Strong Financial Performance 6 SUPRIYA ~ LIFESCIENCE LTD. (in INR Mn) Robust revenue growth Capex Spend … and, focus on profitability 12% 1,623 1,522 8,279 1,457 2,940 2,608 6,965 1,078 2,140 2,091 11111 5,301 5,703 949 1,880 1,880 4,609 1,518 1,289 1,191 11111 FY22 FY23 FY24 FY25 FY26
Slide 30: Working Capital Break-up
Working Capital Break-up G SUPRIYA LIFESCIENCE LTD. (in days) Inventory Receivables 233 198 197 78 172 73 71 72 165 61 FY22 FY23 FY24 FY25 FY26 FY22 FY23 FY24 FY25 FY26 Payables Net Working Capital 113 112 105 235 196 158 170 59 124 49 FY22 FY23 FY24 FY25 FY26 FY22 FY23 FY24 FY25 FY26 29
Slide 31: Future Outlook
; SUPRIYA Outlook Ss LIFESCIENCE LTD.
Slide 32: Future Outlook
Future Outlook G SUPRIYA LIFESCIENCE LTD. R&D centres CMO/CDMO space API R&D - • Evaluating opportunity for exclusive manufacturing rights in liquid inhalation products • Ambernath API R&D facility fully commissioned with a team of 16 scientists • GLP-1 portfolio development and supply in progress f
Slide 33: Thank You
Supriya Lifescience Limited CIN: L51900MH2008PLC180452 Mr. Krishna Raghunathan - Chief Financial Officer cfo@supriyalifescience.com www.supriyalifescience.com Ernst & Young LLP Runjhun Jain Sneha Salian +91 98207 20993 +91 98194 30437 runjhun.jain1@in.ey.com sneha2.salian@in.ey.com THANK YOU
Supriya Lifescience — Q2 & H1 FY27 Earnings Presentation on 6ix